@@stockrock @dachopper @MJC73 - anyone else who would like to answer...
I understand that we are meeting OTAT for Potency Essays, I get that...
But, why is the P3 for C19 ARDS dependent on this potency essays?
Given that the recent trial we had, sponsored by NIH didn't have potency essays - and yet the trial was allowed to proceed.
It cannot be a safety concern, as where was the duty of care to the 222patients enrolled on the previous C19 ARDS trial?
So I can only conclude that this is an additional/ new FDA requirement to smooth out or pave the way for the possible EUA?
Can I get your thoughts?
Ann: MSB Annual Financial Results and Operational Progress, page-186
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$2.41 |
Change
0.620(34.6%) |
Mkt cap ! $3.084B | |||
| Open | High | Low | Value | Volume |
| $1.90 | $2.48 | $1.90 | $58.82M | 25.68M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 100915 | $2.40 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.41 | 99 | 1 |
View Market Depth
| Last trade - 16.12pm 18/07/2025 (20 minute delay) ? |
| MSB (ASX) Chart |